Wellington Management Group LLP Buys 25,089 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Wellington Management Group LLP grew its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 48.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 76,981 shares of the company’s stock after buying an additional 25,089 shares during the period. Wellington Management Group LLP’s holdings in Lexeo Therapeutics were worth $507,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after purchasing an additional 256,635 shares during the period. Privium Fund Management B.V. acquired a new position in Lexeo Therapeutics in the fourth quarter worth $909,000. Exome Asset Management LLC bought a new stake in Lexeo Therapeutics during the 3rd quarter worth about $797,000. State Street Corp grew its stake in shares of Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after buying an additional 33,013 shares during the last quarter. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $2.14 on Tuesday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $3.25 and its two-hundred day moving average price is $5.90. The firm has a market capitalization of $71.04 million, a P/E ratio of -0.68 and a beta of 1.52. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Analyst Upgrades and Downgrades

LXEO has been the subject of several analyst reports. Royal Bank of Canada lowered their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Leerink Partners lowered their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, March 24th. Chardan Capital cut their price objective on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.